Drug Profile
Research programme: neurodegenerative disorders therapeutics - Academia Sinica/Tikvah Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Academia Sinica
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurodegenerative disorders; Spinal muscular atrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
- 24 Jul 2007 Preclinical trials in Neurodegenerative disorders in USA (unspecified route)